Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - gripa, človek - gripi cepiva, gripi, živo zmanjšan - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. uporaba zdravila fluenz tetra mora temeljiti na uradnih priporočilih.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - benzalkonijev klorid - pastila - benzalkonijev klorid 1 mg / 1 pastila - benzalkonium

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - benzalkonijev klorid - pastila - benzalkonijev klorid 1 mg / 1 pastila - benzalkonium

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - benzalkonijev klorid - pastila - benzalkonijev klorid 1 mg / 1 pastila - benzalkonium

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - benzalkonijev klorid - pastila - benzalkonijev klorid 1 mg / 1 pastila - benzalkonium

Evropska unija - slovenščina - EMA (European Medicines Agency)

vétoquinol sa - torasemid brezvodni - sulfonamide, golo, visoko-strop diuretiki - psi - za zdravljenje kliničnih znakov, vključno z edemom in izlivom, povezanih s kongestivnim srčnim popuščanjem pri psih.

Evropska unija - slovenščina - EMA (European Medicines Agency)

merck sharp & dohme b.v. - insulin glargin - sladkorna bolezen - zdravila, ki se uporabljajo pri diabetesu - zdravljenje diabetesa mellitusa pri odraslih, mladostnikih in otrocih, starih 2 leti in več.

Evropska unija - slovenščina - EMA (European Medicines Agency)

novo nordisk a/s - insulin aspart - sladkorna bolezen - zdravila, ki se uporabljajo pri diabetesu - novorapid je indiciran za zdravljenje diabetesa mellitusa pri odraslih, mladostnikih in otrocih, starih 1 leto in več.

Evropska unija - slovenščina - EMA (European Medicines Agency)

novo nordisk a/s - insulin degludec, liraglutide - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - xultophy je indicirano za zdravljenje odraslih s sladkorno boleznijo tipa 2 za izboljšanje nadzora glycaemic v kombinaciji z ustni-znižanje glukoze zdravil, ko ti sam ali v kombinaciji z agonist receptorjev za glp-1 ali bazalni insulin ne zagotavljajo ustrezno glycaemic nadzor.

Evropska unija - slovenščina - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - imunosupresivi - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. , zdravljenje hude, aktivne in postopno revmatoidni artritis pri odraslih, ki še niso bila obdelana z metotreksatom. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita zmanjšuje stopnja napredovanje skupno škodo, merjeno z x-ray in izboljšuje telesno funkcijo, če bi imeli v kombinaciji z metotreksatom. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita lahko podana kot monotherapy v primeru nestrpnost do metotreksatom ali ko nadaljnje zdravljenje z metotreksatom ni primerno (za učinkovitost v monotherapy glej oddelek 5. adalimumab ni raziskano pri bolnikih, starih manj kot 2 leti. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita zmanjšuje stopnja napredovanje perifernih skupno škodo, merjeno z x-ray pri bolnikih z polyarticular simetrični podtipov bolezni (glej poglavje 5. 1), in izboljša telesno funkcijo. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 in 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.